InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,641.60
(
0.83%
)
Dow Jones
39,308.00
(
-0.06%
)
Brent Oil
87.34
(
0.01%
)
Bitcoin
56,932.81
(
-0.11%
)
Post# of 346046
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

sunstar

Send PM Follow Ignore
Followers 62
Posts 1712
Boards Moderated 0
Alias Born 08/08/2005

sunstar

Re: None

Wednesday, 02/09/2011 6:01:58 PM

Wednesday, February 09, 2011 6:01:58 PM

Post# of 346046
Peregrine’s multiple clinical trials and IST’s are advancing and maturing with a primary goal of achieving an initial FDA approval for bavituximab in oncology.

Company policies and objectives recognize the underlying value of the technological platforms and the potential value of the drug pipeline. The value of even just treating the solid tumor cancers with bavituximab will be immense. Peregrine holds the potential worldwide market for bavituximab: anti-cancer and anti-viral.

Recent monthly PPHM trade volume has markedly increased and remains strong. It appears that quite large new positions in Peregrine have begun to be reported. These seem to be solid markers. Price follows volume.

GLTA this year.

sunstar
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent CDMO News
More CDMO News
InvestorsHub NewsWire

Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM

EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM

BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM

NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM

Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM

VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM

Start posting your company's news
Only $200 per official company press release!